Training Program on Development of Medications for Substance Use Disorder

药物滥用药物开发培训计划

• 批准号: 10630338
• 负责人: Raymond G. Booth
• 金额: $ 33.9万
• 依托单位: NORTHEASTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630338
• 关键词: Development; Pharmaceutical Preparations; Substance Use Disorder; Training Programs

This T32 application, the Center for Drug Discovery “Training Program on Medications Development for Substance Use Disorder (SUD)”, is to provide broad training to PhD students and postdoctoral scientists on drug development for SUD. The Training Program rationale is driven by the socioeconomic burden and medical need associated with the lack of safe and effective medicines to treat SUD in the US and globally. The Training Program blends mentorship, coursework, and research activities in a setting with state-of-the-art facilities. The goal of training is to equip trainees to develop as productive biomedical research scientists, with consummate expertise in SUD pharmacotherapies research. The main locus of this training program is the Center for Drug Discovery (CDD) at Northeastern University that has unique technologies housed in one cohesive unit, including, high-throughput synthetic chemistry and pharmacological activity screening; mass spectrometry-based genomics, proteomics and metabolomics, as well as, bioanalytical analysis; high-resolution NMR technologies; and in vivo MRI imaging. Notably, CDD Training Program faculty includes SUD researchers at Harvard Medical School and McLean Psychiatric Hospital, as well as, at Tufts University and Medical Center. Moreover, CDD Training Program consultants include drug development scientists from the pharmaceutical and biotechnology industrial community in Boston. All participating institutions are within an 8-mile radius of each other in the metropolitan Boston area. The Training Program presents a premiere discovery and translational node to address the appalling morbidity and mortality associated with apparent lack of effective medications for opioid use disorder and complete absence of approved medications for SUD associated with cannabinoids and psychostimulants—it appears that repurposing of old drugs has not worked and the lack of novel medicines from pharmaceutical industry and federal laboratories provides strong rationale for our academic-based training program on novel medication development for SUD, with its unique multi-disciplinary, multi-institutional approach. A unique feature of the Training Program is engagement of junior faculty, including, from the Medications Development Branch of the NIDA Intramural Program, to provide for the next generation of SUD medication development scientists. Training Program faculty assist pre- and postdoctoral trainees to develop scientific integrity, collaboration, grantsmanship, and presentation skills, as well as, expertise in methodologies, including, synthetic chemistry, molecular and behavioral pharmacology, drug pharmacokinetics and metabolism, “omics” (pharmacogenomics, proteomics, metabolomics), and neuroimaging. In addition to core research ethics training, there will be ethics roundtable discussions. Some other features of the Training Program include postdoctoral–predoctoral trainee collaboration, a trainees’ seminar series, and trainee engagement with SUD scientists at the annual CDD/NIDA-sponsored symposium, Chemistry and Pharmacology of Drug Abuse.

此 T32 申请是药物发现中心“药物开发培训计划” 物质使用障碍（SUD）”，旨在为博士生和博士后科学家提供有关药物的广泛培训 SUD 的发展理由是社会经济负担和医疗需求。 与美国和全球缺乏安全有效的治疗 SUD 的药物有关。 该项目在拥有最先进设施的环境中融合了指导、课程作业和研究活动。 培训的目标是使受训者成为富有成效的生物医学研究科学家，并具有完善的能力 SUD 药物疗法研究方面的专业知识 该培训项目的主要地点是药物中心。 东北大学的 Discovery (CDD) 将独特的技术集中在一个有凝聚力的单元中，包括： 基于高通量合成化学和药理活性筛选； 基因组学、蛋白质组学和代谢组学以及生物分析技术； 值得注意的是，CDD 培训项目的教员包括哈佛医学院的 SUD 研究人员。 学校和麦克莱恩精神病医院，以及塔夫茨大学和医疗中心。 培训计划顾问包括来自制药和生物技术领域的药物开发科学家 波士顿工业社区内所有参与机构均在 8 英里半径范围内。 培训计划为波士顿大都会地区提供了一个首屈一指的发现和转化节点。 解决与明显缺乏有效阿片类药物相关的令人震惊的发病率和死亡率 使用障碍和完全没有批准的与大麻素相关的 SUD 药物，以及 精神兴奋剂——旧药物的重新利用似乎并没有发挥作用，而且缺乏新药 制药行业和联邦实验室为我们的学术培训提供了强有力的理由 SUD 的新药开发项目，具有独特的多学科、多机构 培训计划的一个独特之处是初级教师的参与，包括来自初级教师的参与。 NIDA 校内计划药物开发分部，为下一代 SUD 提供支持 药物开发科学家培训计划的教师协助博士前和博士后学员进行开发 科学诚信、协作、资助和演讲技巧，以及方法学方面的专业知识， 包括合成化学、分子和行为药理学、药物药代动力学和代谢， 除了核心研究伦理之外，“组学”（药物基因组学、蛋白质组学、代谢组学）和神经影像学。 培训期间，还将进行道德圆桌讨论。培训计划的其他一些特点包括 博士后-博士前实习生合作、实习生研讨会系列以及实习生与 SUD 的互动 科学家们参加了 CDD/NIDA 主办的年度药物滥用化学和药理学研讨会。